Part 2 for Healthy Subjects

Quotient Sciences Miami, Miami, FL
Healthy SubjectsSulfasalazine - Drug
Eligibility

Study Summary

The purpose of this study is to evaluate the effects of BMS-986371 on the drug levels of methotrexate, sulfasalazine and their main metabolites in healthy male adult participants.

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Study Objectives

3 Primary · 4 Secondary · Reporting Duration: Up to 30 days post participant's last study treatment

Up to 22 days
AUC(0-T)
AUC(INF)
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])
Cmax
Maximum observed plasma concentration (Cmax)
Day 30
Number of participants with adverse events (AEs)

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Part 2
1 of 2
Part 1
1 of 2

Experimental Treatment

30 Total Participants · 2 Treatment Groups

Primary Treatment: Part 2 · No Placebo Group · Phase 1

Part 2Experimental Group · 4 Interventions: Sulfasalazine, BMS-986371, Leucovorin, Methotrexate · Intervention Types: Drug, Drug, Drug, Drug
Part 1Experimental Group · 3 Interventions: BMS-986371, Leucovorin, Methotrexate · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sulfasalazine
2016
Completed Phase 4
~1860
BMS-986371
2022
Completed Phase 1
~30
Leucovorin
2005
Completed Phase 4
~5440
Methotrexate
2013
Completed Phase 4
~3800

Trial Logistics

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 30 days post participant's last study treatment

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,537 Previous Clinical Trials
4,019,305 Total Patients Enrolled

Eligibility Criteria

Age 18 - 50 · Male Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

To what demographic does the enrollment criteria for this clinical trial apply?

"For admittance to this clinical trial, individuals need to possess healthy subject (hs) status and be between 18 and 50 years old. 32 participants are required in total." - Anonymous Online Contributor

Unverified Answer

What purpose does this research endeavor aim to achieve?

"As stated by the research sponsor, Bristol-Myers Squibb, primary outcomes over a maximum of 22 days will be monitored to measure peak plasma concentration (Cmax). Secondary objectives such as the number of patients experiencing adverse events in Parts 1 and 2, Cmax in Part 2, and area under curve (AUC(0-T)) measurements in Part 2 are also being assessed." - Anonymous Online Contributor

Unverified Answer

How many participants are being selected to join this trial?

"Affirmative. According to clinicaltrials.gov, recruitment for this experiment is in full swing; having first been posted on September 6th 2022 and most recently updated on October 10th of the same year. 32 volunteers are needed across one location for completion of the study." - Anonymous Online Contributor

Unverified Answer

Does the eligibility of this research include individuals aged 65 or above?

"This particular clinical trial calls for participants between the ages of 18 and 50. For those under 18, there are approximately fifty trials they can enrol in while seniors over 65 have more than three hundred seventy-three options available to them." - Anonymous Online Contributor

Unverified Answer

Is there capacity for additional participants in this research project?

"The clinical trial, posted on September 6th 2022, is recruiting patients. The details have been recently updated and are available as of October 10th 2022." - Anonymous Online Contributor

Unverified Answer

What hazards do people face when engaging in Part 2?

"Unfortunately, the safety of Part 2 is not well supported by data yet and it thus received a score of 1 on our ranking scale. This assessment was made due to this being an initial stage trial with little evidence for its efficacy or protection from harm." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.